Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 Sep 11;: Authors: Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B Abstract PURPOSE: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant prostate cancer without detectable metastases by conventional imaging (nmCRPC). Prostate-specific membrane antigen ligand positron-emission tomography (PSMA-PET) detects prostate cancer with superior sensitivity to conventional imaging, but its performance in nmCRPC remains largely unknown. We characterized cancer burden in high-risk nmCRPC patients using PSMA-PET. EXPERIMENTAL DESIGN: We retrospectively included 200 patients with nmCRPC, prostate-specific antigen (PSA)>2 ng/mL, and high risk for metastatic disease (PSA doubling time [PSADT] ≤10 months and/or Gleason score ≥8) from six high-volume PET centers. We centrally reviewed PSMA-PET detection rate for pelvic disease and distant metastases (M1). We further evaluated SPARTAN patients stratified by risk factors for PSMA-PET-detected M1 disease. RESULTS: PSMA-PET was positive in 196/200 patients. Overall, 44% had pelvi...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Related Links:

Abstract Aim: To determine the effect of bulking and osmotic laxation regimens on reducing rectal gas in patients receiving external beam radiation therapy for prostate cancer. Methods: A single blinded randomized controlled trial was conducted. Participants assigned to the intervention group (IG) were instructed to consume a bulking laxative and probiotic and the standard care group (SC) instructed to consume an osmotic laxative. Both groups followed a standard low gas diet. Rectal gas ratings were determined from cone-beam computed tomography (CBCT) scans. Dietary and laxative compliance, bowel habits, fiber and...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
In this study we evaluate the lesion detection efficacy of18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.MethodsA total of 248 consecutive patients were evaluated and underwent scanning with18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120  min after injection of a median dose of 311 MBq18F-DCFPyL.ResultsIn 214 out of 248 PET/CT scans (86.3%), at least one lesion sug...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Publication date: Available online 18 June 2019Source: The LancetAuthor(s): Anders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, Camilla Thellenberg-Karlsson, Morten Hoyer, Magnus Lagerlund, Jon Kindblom, Claes Ginman, Bengt Johansson, Kirsten Björnlinger, Mihajl Seke, Måns Agrup, Per Fransson, Björn Tavelin, David Norman, Björn Zackrisson, Harald Anderson, Elisabeth Kjellén, Lars Franzén, Per NilssonSummaryBackgroundHypofractionated radiotherapy for prostate cancer has gained increased attention due to its proposed high radiation-fraction sensitivity. Recent reports from studies compar...
Source: The Lancet - Category: General Medicine Source Type: research
Conclusions: The trial was stopped after the first step analysis for absence of response to Radium 223 according to PERCIST criteria at FDG PET in patients with bone metastases from RAI refractory DTC. Furthermore awareness of hematological toxicity in case of previously RAI and external radiation therapy is needed.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Therapy Concepts I: Endocrinology Source Type: research
592Objectives: 18F-rhPSMA-7 is a new theranostic PSMA-targeting agent which allows fast radiolabeling with 18F and radiometals. This retrospective analysis investigates the efficacy of 18F-rhPSMA-7 PET/computed tomography (CT) in patients with biochemical recurrence of prostate cancer following curative-intent primary treatment with external beam radiotherapy (EBRT) or brachytherapy. Methods: Datasets from patients with non-castrate biochemical recurrence of prostate cancer after treatment with EBRT or brachytherapy who underwent 18F-rhPSMA-7 PET/CT at either the Technical University Munich or Ludwig-Maximillian University...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Diagnosis I Source Type: research
649Objectives: 18F-rhPSMA-7 is a new theranostic PSMA-targeting agent which allows fast radiolabeling with 18F and radiometals and is associated with only minimal renal excretion. This retrospective analysis evaluated the efficacy of 18F-rhPSMA-7 PET in patients with biochemical recurrence (BCR) of prostate cancer after radical prostatectomy. Methods: Datasets from patients with non-castrate BCR after radical prostatectomy who underwent 18F-rhPSMA-7 PET/CT or PET/MRI at our institution between June 2017 and June 2018 were retrospectively reviewed. Images were reviewed by an experienced nuclear medicine physician and all le...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Diagnosis II Source Type: research
The objective of this prospective study was to evaluate the lesion detection rate, safety, and impact on management of [18F]DCFPyL PET/CT for prostate cancer imaging. Methods: An interim analysis of the first 208 [18F]DCFPyL PET/CT patient scans done in an investigator-initiated clinical trial (clinicaltrials.gov identifier NCT03181867) was conducted. The inclusion criteria were: (1) known prostate cancer with biochemical recurrence after initial curative therapy with radical prostatectomy with PSA> 0.4 ng/mL followed by an additional measurement showing increase; (2) known prostate cancer with biochemical recurrence af...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Diagnosis II Source Type: research
Conclusion: 18F DCFPyL PET/CT is a promising diagnostic tool in the work-up of patients with BCR PC as not only did it identify sites of recurrent disease but it also changed clinical management in 28% of participants with negative conventional imaging in this cohort.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Diagnosis II Source Type: research
Conclusions: 18F-DCFPyL-PET imaging is helpful in identifying suspicious lesions in 76.9% of patients with biochemical recurrence prostate cancer; and more importantly, it reveals a high number of positive findings in the range of low PSA values (
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Diagnosis II Source Type: research
1560Introduction: Prostate cancer is the most common solid cancer in men. Its incidence increases with age and thus is a major health concern for the ageing population of the world. Following definitive treatment of prostate cancer by radical prostatectomy (RP) or radiotherapy, cancer recurrence is heralded by an increase in serum prostate-specific antigen (PSA) which is called biochemical recurrence. Depending on the patient population studied, 15-40% of patients experience rising serum PSA levels. Determining whether recurrence is local (within the prostate or at the urethral/bladder anastomosis), regional (pelvic) or di...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate/GU Imaging Posters Source Type: research
More News: Cancer | Cancer & Oncology | Pathology | PET Scan | Prostate Cancer | Radiation Therapy | Study